Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.

Trial Details

NCT ID
NCT06288360
Phase
PHASE2
Sponsor
Tongji Hospital
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Camrelizumab
  • Paclitaxel-albumin
  • Cisplatin
  • radical surgery
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • FIGO 2018 stage IB3, IIA2, or IIB/IIIC1r (tumor size\>4cm) cervical cancer and without any treatment (After undergoing gynecological examinations b…
  • Has at least one measurable lesion based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. In principle, the size of the lesio…
  • Histologically confirmed squamous carcinoma, adenocarcinoma (common type) or adenosquamous carcinoma of the cervix;
  • Negative PD-L1 expression on preoperative pathological examination (Combined positive score \< 1);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →